Daily Briefing – June 7: Sunday reset after the AI-chip shock, hot payrolls, higher yields, Marvell’s S&P 500 setup and a week packed with Apple, Oracle, inflation data and biotech catalyst discipline

The June 7 briefing is a Sunday reset, not a quiet weekend note. Friday’s market shock changed the short-term tone: the May jobs report came in stronger than expected, with U.S. nonfarm payrolls rising by 172,000 and unemployment holding at 4.3%, giving traders less room to price quick Fed easing. The result was a sharp repricing in yields, a broad risk-off session and heavy pressure on the most crowded growth trades. The Nasdaq lost more than 4%, the S&P 500 dropped more than 2.5%, and semiconductors suffered one of their worst sessions in years as the AI trade finally met a serious valuation stress test. Broadcom remains the center of the reset because the market’s reaction showed that strong AI exposure is no longer enough by itself: guidance, margins, backlog quality and valuation now need to clear a much higher bar. Marvell stays important for the opposite reason: it sold off with the group, but it also gained a new benchmark-flow angle after S&P Dow Jones Indices selected Marvell and Flex for S&P 500 inclusion before the open on June 22. That makes MRVL one of the cleanest Monday watch names for both AI custom silicon and index-demand follow-through. The week ahead adds more pressure points. Apple’s WWDC will test whether the market still rewards AI product narratives, Oracle earnings will test AI infrastructure profitability, CPI/PPI will test the rate story, and Sunday evening futures will show whether Friday was a healthy reset or the first leg of a deeper derisking phase. For biotech, the message is even stricter: after ASCO, the tape is moving away from headline excitement and back toward evidence quality, regulatory path, PDUFA timing, cash runway, dilution risk and FDA-specific execution.

• AVGO— Broadcom remains the key AI valuation-reset name after the post-earnings reaction spilled into the broader semiconductor complex and raised the bar for every crowded AI winner.AI Earnings
• MRVL— Marvell is now a double catalyst: an AI custom-silicon story and an S&P 500 inclusion story, with index entry scheduled before the open on June 22.AI / Index
• FLEX— Flex joins Marvell in the S&P 500 rebalance, giving the contract-manufacturing and data-center hardware supply chain another benchmark-flow angle.Index Flow
• NVDA— Nvidia remains the anchor of the AI market, but Friday proved that even the strongest leader can be pulled lower when yields rise and semiconductor multiples compress.AI Anchor
• AMD / INTC— AMD and Intel remain breadth checks for the chip tape; after Friday’s washout, follow-through matters more than catch-up narratives.Chip Breadth
• AAPL— Apple’s WWDC becomes a major AI-sentiment event this week because the market wants clearer proof that Apple can turn AI features into product momentum.WWDC / AI
• ORCL— Oracle earnings will be a major AI-infrastructure read because the market wants evidence that cloud demand, capex and AI backlog can translate into profitable growth.AI Earnings
• GME— GameStop remains a retail-flow and special-situation watch after quarterly revenue growth and a new $2 billion share repurchase authorization kept the name active.Retail / Buyback
• PHAR— Pharming remains a fresh FDA-calendar name after FDA acceptance of the Joenja/leniolisib pediatric sNDA resubmission for APDS in children aged 4 to 11, with an October 24, 2026 PDUFA date.FDA / Rare Disease
• URGN / TEVA— UroGen and Teva remain on the legal/IP watchlist after the JELMYTO patent-litigation settlement, which allows potential Teva generic entry beginning September 15, 2030 if approved by FDA.Legal / IP
• IDYA— IDEAYA remains one of the cleaner post-ASCO regulatory stories because darovasertib plus crizotinib has a visible metastatic uveal melanoma path, but FDA alignment remains the key filter.ASCO / Regulatory
• IMRX— Immuneering remains a pancreatic cancer validation story after ASCO, but the new risk-off tape makes Phase 3 design, cash runway and financing discipline more important.ASCO / Pancreatic
• NXTC— NextCure remains an early ADC watch around SIM0505 and CDH6, but the market will demand more mature patient numbers, safety clarity and capital visibility.ASCO / ADC
• IMTX— Immatics remains one of the stronger institutional cell-therapy stories from ASCO, with PRAME TCR-T execution and the SUPRAME Phase 3 path still central.ASCO / Cell Therapy
• COGT / BBIO / VERA / CORT / CELC / CAPR— The FDA catalyst basket stays important because higher yields usually make biotech more selective, increasing the premium on clean PDUFA timing, label setup and cash runway.PDUFA Watch

• Payrolls are now the anchor— May payrolls rose by 172,000 and unemployment held at 4.3%, reducing the market’s room to price fast Fed easing.Jobs
• Yields matter again— The stronger labor print pushed investors back toward the higher-for-longer debate, which is painful for long-duration growth, small caps and cash-burning biotech.Rates
• Nasdaq shock— Friday’s tech-heavy selloff was not a normal pause: the Nasdaq fell more than 4%, and the semiconductor complex took the hardest hit.Tech
• SOXX stress test— The chip tape suffered one of its worst sessions in years, making Monday’s follow-through critical for AI sentiment.Semis
• AI is not broken, but stricter— The infrastructure theme remains real, but the market is now demanding upside, margin protection, guidance strength and valuation discipline at the same time.AI Valuation
• Apple is the product test— WWDC will show whether investors still reward AI software narratives or demand immediate evidence of user adoption and monetization.AAPL
• Oracle is the infrastructure test— Oracle earnings will matter because investors want to see whether AI cloud demand can support margins, capex and durable revenue acceleration.ORCL
• Inflation data returns— CPI and PPI are the next macro checks because Friday’s payrolls already made the Fed setup more difficult for risk assets.CPI / PPI
• Oil still matters— Middle East risk keeps crude and inflation expectations relevant, especially if energy adds pressure on top of hot labor data.Oil / Geo
• ASCO digestion continues— Biotech is past the easy headline stage. The tape is separating registrational paths from early signals, biomarker stories and single-arm datasets.Biotech
• FDA policy watch— FDA’s June draft guidance on leveraging prior knowledge in gene therapy development is constructive for rare-disease sponsors, but company-specific approvability still matters.Regulatory
• Small-cap filter— IWM and XBI are the breadth checkpoints. If they lag while mega-cap AI tries to stabilize, the rally remains narrow and fragile.Breadth